Development of FinaBio’s CRM197, EcoCRM® and Ready-to-ConjugateTM carrier proteins. Presented April 15, 2020 to the Canadian Glycomics Network About the Canadian Glycomics Network In 2015, the Canadian glycomics research community mobilized to…
Pneumosil®, from Serum Institute of India achieves WHO prequalification. At $2 per dose, Pneumosil® will be 30% less expensive than the current GAVI price for pneumococcal vaccines. It will also…
PATH (path.org), an organization promoting health in low income countries, has published an article on their smaller partners, including Fina Biosolutions. FinaBio has worked with PATH on conjugate vaccines for…
A meningococcal conjugate vaccine using chemistry developed at Fina Biosolutions has entered a pivotal phase III trial. FinaBio patents for CPIP conjugation were exclusively licensed to the Serum Institute of…
Fina Biosolutions LLC of Rockville, MD has signed a development agreement for two conjugate vaccines with the Chinese Institute of Medical Biology (Kunming), part of the Chinese Academy of Medicine.…
BioTalk summary here. Listen now on Google Play bit.ly/2CzdnA9, iTunes, apple.co/2Arsfze, TuneIn bit.ly/2M60Wmx.
The Johns Hopkins Medical & Surgical Association will present Fina Biosolutions founder and scientific director, Andrew Lees,their “Distinguished Alumni Award”. The award will be presented at theirannual Reunion & Alumni…
For Immediate Release: Fina Biosolutions’ Licensee Successfully Completes a Phase 3 Study and Enters World Health Organization (WHO) Registration for Pneumosil® Serum Institute of India completes a Phase 3 clinical trial…
Andrew Lees, Fina Biosolutions’ scientific director, speaks on the challenges of purifying conjugate vaccines and vaccine components. Ion Exchange: Pore choices and ion clouds: aspects of resin architecture that affect…
Last month, the Maryland Tech Council stopped by Fina Biosolutions, where they met with Founder, CEO and Chief Scientific Officer, Dr. Andrew Lees. Dr. Lees was a gracious host, giving…